Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Background and aims Sodium-glucose cotransporter-2 (SGLT2) inhibitors are a novel class of drugs that lower glucose by inducing renal glycosuria. We aimed to explore whether SGLT2 inhibitor added to the usual care for patients with type 2 diabetes mellitus (T2DM) and biopsy-proven nonalcoholic steatohepatitis (NASH) will benefit NASH histology. Methods In this investigator-initiated, single-arm, open-label, pilot study, nine biopsy-proven NASH patients with T2DM were given empagliflozin 25 mg daily for 24 weeks. Liver biopsy was repeated at the end of treatment. The histological outcomes were compared with the placebo group of a previous 48-week clinical trial. Results There was a significant reduction in body mass index (median change, Δ = -0.7 kg per m 2 , p = 0.011), waist circumference (Δ = -3 cm, p = 0.033), systolic blood pressure (Δ = -9 mmHg, p = 0.024), diastolic blood pressure (Δ = -6 mmHg, p = 0.033), fasting blood glucose (Δ = -1.7 mmol/L, p = 0.008), total cholesterol (Δ = -0.5 mmol/L, p = 0.011), gamma glutamyl transpeptidase (Δ = -19 U/L, p = 0.013), volumetric liver fat fraction (Δ = -7.8%, p = 0.017), steatosis (Δ = -1, p = 0.014), ballooning (Δ = -1, p = 0.034), and fibrosis (Δ = 0, p = 0.046). All histological components either remained unchanged or improved, except in one patient who had worsening ballooning. Empagliflozin resulted in significantly greater improvements in steatosis (67% vs. 26%, p = 0.025), ballooning (78% vs. 34%, p = 0.024), and fibrosis…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Of note, the amount of weight loss determined the amount of liver lipid reduction for both empagliflozin [98] and canagliflozin [155] in respective RCTs.”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [155]
In the citing paper
“Utilizing imaging methods, canagliflozin failed to induce a statistically significant reduction in liver lipid content [152]”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [152]
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
The metabolic syndrome—a new worldwide definition
Alberti, K. G. M., Zimmet, P., & Shaw, J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67402-8 · Cited by 9,352
Chalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K., Charlton, M., & Sanyal, A. J. (2012) · Hepatology · doi:10.1002/hep.25762 · Cited by 3,803
Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203
Wong, R. J., Aguilar, M., Cheung, R., Perumpail, R. B., Harrison, S. A., Younossi, Z. M., & Ahmed, A. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.11.039 · Cited by 1,819
Musso, G., Gambino, R., Cassader, M., & Pagano, G. (2011) · Annals of Medicine · doi:10.3109/07853890.2010.518623 · Cited by 1,293
Cryer, P. E., Axelrod, L., Grossman, A. B., Heller, S. R., Montori, V. M., Seaquist, E. R., & Service, F. J. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1410 · Cited by 1,277
Ratziu, V., Harrison, S. A., Francque, S., Bedossa, P., Lehert, P., Serfaty, L., Romero-Gomez, M., Boursier, J., Abdelmalek, M., Caldwell, S., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.038 · Cited by 1,035
Cited by
Eslam, M., Sarin, S. K., Wong, V. W.-S., Fan, J.-G., Kawaguchi, T., Ahn, S. H., Zheng, M.-H., Shiha, G., Yilmaz, Y., Gani, R., et al. (2020) · Hepatology International · doi:10.1007/s12072-020-10094-2 · Cited by 833
Self-citationThe complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments
Targher, G., Corey, K. E., Byrne, C. D., & Roden, M. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00448-y · Cited by 850
Tanase, D. M., Gosav, E. M., Costea, C. F., Ciocoiu, M., Lacatusu, C. M., Maranduca, M. A., Ouatu, A., & Floria, M. (2020) · Journal of Diabetes Research · doi:10.1155/2020/3920196 · Cited by 627
“Also, empagliflozin [187, 188] and dapagliflozin [189, 190] administration showed similar beneficial results.”
BackgroundBadmus, O. O., Hillhouse, S. A., Anderson, C. D., Hinds, T. D., & Stec, D. E. (2022) · Clinical Science · doi:10.1042/cs20220572 · Cited by 370
Xu, X., Poulsen, K. L., Wu, L., Liu, S., Miyata, T., Song, Q., Wei, Q., Zhao, C., Lin, C., & Yang, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01119-3 · Cited by 359
Kahl, S., Gancheva, S., Straßburger, K., Herder, C., Machann, J., Katsuyama, H., Kabisch, S., Henkel, E., Kopf, S., Lagerpusch, M., et al. (2020) · Diabetes Care · doi:10.2337/dc19-0641 · Cited by 360
Nonalcoholic fatty liver disease in adults: current concepts in etiology, outcomes, and management
Marjot, T., Moolla, A., Cobbold, J. F., Hodson, L., & Tomlinson, J. W. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz009 · Cited by 228
An international multidisciplinary consensus statement on MAFLD and the risk of CVD
Zhou, X.-D., Targher, G., Byrne, C. D., Somers, V., Kim, S. U., Chahal, C. A. A., Wong, V. W.-S., Cai, J., Shapiro, M. D., Eslam, M., et al. (2023) · Hepatology International · doi:10.1007/s12072-023-10543-8 · Cited by 194
Self-citationEslam, M., Fan, J.-G., Yu, M.-L., Wong, V. W.-S., Cua, I. H., Liu, C.-J., Tanwandee, T., Gani, R., Seto, W.-K., Alam, S., et al. (2025) · Hepatology International · doi:10.1007/s12072-024-10774-3 · Cited by 170
Self-citationTaheri, H., Malek, M., Ismail-Beigi, F., Zamani, F., Sohrabi, M., Reza babaei, M., & Khamseh, M. E. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01498-5 · Cited by 188
NAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment
Targher, G., Corey, K. E., & Byrne, C. D. (2021) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.101215 · Cited by 165
Zhou, X.-D., Cai, J., Targher, G., Byrne, C. D., Shapiro, M. D., Sung, K.-C., Somers, V. K., Chahal, C. A. A., George, J., Chen, L.-L., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01697-0 · Cited by 168
Chehrehgosha, H., Sohrabi, M. R., Ismail-Beigi, F., Malek, M., Reza Babaei, M., Zamani, F., Ajdarkosh, H., Khoonsari, M., Fallah, A. E., & Khamseh, M. E. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01011-3 · Cited by 173
Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?
Huttasch, M., Roden, M., & Kahl, S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155937 · Cited by 169
Metabolic liver disease in diabetes – From mechanisms to clinical trials
Dewidar, B., Kahl, S., Pafili, K., & Roden, M. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154299 · Cited by 158
Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD
Takahashi, H., Kessoku, T., Kawanaka, M., Nonaka, M., Hyogo, H., Fujii, H., Nakajima, T., Imajo, K., Tanaka, K., Kubotsu, Y., et al. (2022) · Hepatology Communications · doi:10.1002/hep4.1696 · Cited by 153
Mantovani, A., Petracca, G., Csermely, A., Beatrice, G., & Targher, G. (2020) · Metabolites · doi:10.3390/metabo11010022 · Cited by 134
Non‐alcoholic fatty liver disease and type 2 diabetes: An update
Lee, C., Lui, D. T. W., & Lam, K. S. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13756 · Cited by 160
Takeshita, Y., Honda, M., Harada, K., Kita, Y., Takata, N., Tsujiguchi, H., Tanaka, T., Goto, H., Nakano, Y., Iida, N., et al. (2022) · Diabetes Care · doi:10.2337/dc21-2049 · Cited by 145
The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease
Romero, F. A., Jones, C. T., Xu, Y., Fenaux, M., & Halcomb, R. L. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01701 · Cited by 120
From NAFLD to MAFLD: Definition, Pathophysiological Basis and Cardiovascular Implications
Boccatonda, A., Andreetto, L., D’Ardes, D., Cocco, G., Rossi, I., Vicari, S., Schiavone, C., Cipollone, F., & Guagnano, M. T. (2023) · Biomedicines · doi:10.3390/biomedicines11030883 · Cited by 130
Drożdż, K., Nabrdalik, K., Hajzler, W., Kwiendacz, H., Gumprecht, J., & Lip, G. Y. H. (2021) · Nutrients · doi:10.3390/nu14010103 · Cited by 122
Kinoshita, T., Shimoda, M., Nakashima, K., Fushimi, Y., Hirata, Y., Tanabe, A., Tatsumi, F., Hirukawa, H., Sanada, J., Kohara, K., et al. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13279 · Cited by 121
Xian, Y., Weng, J., & Xu, F. L. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001263 · Cited by 130
Moon, J. S., Hong, J. H., Jung, Y. J., Ferrannini, E., Nauck, M. A., & Lim, S. K. (2022) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2022.03.005 · Cited by 86
Rajput, D. S., Basha, S. M., Xin, Q., Gadekallu, T. R., Kaluri, R., Lakshmanna, K., & Maddikunta, P. K. R. (2021) · Journal of Ambient Intelligence and Humanized Computing · doi:10.1007/s12652-021-03154-4 · Cited by 80
Time to Include Nonalcoholic Steatohepatitis in the Management of Patients With Type 2 Diabetes
Cusi, K. (2020) · Diabetes Care · doi:10.2337/dci19-0064 · Cited by 67
Renal physiology of glucose handling and therapeutic implications
Cherney, D. Z. I., Kanbay, M., & Lovshin, J. A. (2020) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfz230 · Cited by 73
Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH
Svegliati-Baroni, G., Patrício, B., Lioci, G., Macedo, M. P., & Gastaldelli, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165820 · Cited by 66
Antidiabetic Drugs and Statins in Nonalcoholic Fatty Liver Disease
Kothari, S., Dhami-Shah, H., & Shah, S. R. (2019) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2019.06.003 · Cited by 68
Current and emerging pharmacotherapeutic interventions for the treatment of liver fibrosis
Lambrecht, J., van Grunsven, L. A., & Tacke, F. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1774553 · Cited by 64
Ahmed, S. A., El-Sayed, M. M., Kandeil, M. A., & Khalaf, M. M. (2022) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2022.03.005 · Cited by 68
Diabetes as a risk factor for MASH progression
Gancheva, S., Roden, M., & Castéra, L. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111846 · Cited by 65
Arai, T., Atsukawa, M., Tsubota, A., Mikami, S., Uojima, H., Yoshikata, K., Ono, H., Kawano, T., Yoshida, Y., Tanabe, T., et al. (2022) · Hepatology Communications · doi:10.1002/hep4.2069 · Cited by 55
Maldonado-Rojas, A. D. C., Zuarth-Vázquez, J. M., Uribe, M., & Barbero-Becerra, V. J. (2023) · Annals of Hepatology · doi:10.1016/j.aohep.2023.101182 · Cited by 60
Systemic and organ-specific anti-inflammatory effects of sodium-glucose cotransporter-2 inhibitors
Mashayekhi, M., Safa, B. I., Gonzalez, M. S. C., Kim, S. F., & Echouffo-Tcheugui, J. B. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.02.003 · Cited by 56
Pharmacotherapy for Non-Alcoholic Fatty Liver Disease: Emerging Targets and Drug Candidates
Александровна, П. В., Bezborodkina, N. N., & Okovityi, S. V. (2022) · Biomedicines · doi:10.3390/biomedicines10020274 · Cited by 58
Cusi, K. (2020) · Liver International · doi:10.1111/liv.14350 · Cited by 51
Metabolic syndrome and its association with nonalcoholic steatohepatitis
Bril, F., Sanyal, A., & Cusi, K. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.01.002 · Cited by 52
Akuta, N., Kawamura, Y., Fujiyama, S., Saito, S., Muraishi, N., Sezaki, H., Hosaka, T., Kobayashi, M., Kobayashi, M., Arase, Y., et al. (2022) · Hepatology Communications · doi:10.1002/hep4.2005 · Cited by 49
Akuta, N., Kawamura, Y., Fujiyama, S., Sezaki, H., Hosaka, T., Kobayashi, M., Kobayashi, M., Saitoh, S., Suzuki, F., Suzuki, Y., et al. (2020) · Internal Medicine · doi:10.2169/internalmedicine.4398-19 · Cited by 48
“Similar re-sults using other SGLT2is were also reported by another group (significant improvements at 24 weeks in steatosis, ballooning and fibrosis] (10), highlighting the therapeutic potential of SGLT2is as effective agents against NAFLD complicated with T2DM.”
SGLT2 Inhibitors in Liver Patients
Hsiang, J. C., & Wong, V. W.-S. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.05.021 · Cited by 48
Ganguli, S., Deleeuw, P., & Satapathy, S. K. (2019) · Hepatic Medicine Evidence and Research · doi:10.2147/hmer.s188991 · Cited by 50
Liver-targeting drugs and their effect on blood glucose and hepatic lipids
Gastaldelli, A., Stefan, N., & Häring, H. (2021) · Diabetologia · doi:10.1007/s00125-021-05442-2 · Cited by 49
Chan, W., Tan, S., Chan, S., Lee, Y., Tee, H., Mahadeva, S., Goh, K., Ramli, A. S., Mustapha, F., Kosai, N. R., et al. (2022) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15787 · Cited by 46
Self-citationIntegrating liver endpoints in clinical trials of cardiovascular and kidney disease
Zannad, F. M., Sanyal, A. J., Butler, J., Miller, V., & Harrison, S. A. (2024) · Nature Medicine · doi:10.1038/s41591-024-03223-z · Cited by 52
Wang, Y., Ding, Y., Sun, P., Zhang, W., Xin, Q., Wang, N., Niu, Y., Chen, Y., Luo, J., Lu, J., et al. (2022) · Antioxidants · doi:10.3390/antiox11050799 · Cited by 47
Non-Invasive Measurement of Hepatic Fibrosis by Transient Elastography: A Narrative Review
Rinaldi, L., Giorgione, C., Mormone, A., Esposito, F., Rinaldi, M., Berretta, M., Marfella, R., & Romano, C. P. (2023) · Viruses · doi:10.3390/v15081730 · Cited by 53
Changing clinical management of NAFLD in Asia
Nakatsuka, T., Tateishi, R., & Koike, K. (2021) · Liver International · doi:10.1111/liv.15046 · Cited by 52
The interplay between nonalcoholic fatty liver disease and atherosclerotic cardiovascular disease
Finney, A. C., Das, S., Kumar, D., McKinney, M. P., Cai, B., Yurdagul, A., & Rom, O. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1116861 · Cited by 40
Metabolic dysfunction-associated fatty liver disease: current therapeutic strategies
Al-Hashmi, K., Giglio, R. V., Stoian, A. P., Patti, A. M., Waili, K. A., Al‐Rasadi, K., Ciaccio, M., & Rizzo, M. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1355732 · Cited by 42
MASLD and MASH at the crossroads of hepatology trials and cardiorenal metabolic trials
Zannad, F. M., Sanyal, A. J., Butler, J., Ferreira, J. P., Girerd, N., Miller, V., Pandey, A., Parikh, C. R., Ratziu, V., Younossi, Z. M., et al. (2024) · Journal of Internal Medicine · doi:10.1111/joim.13793 · Cited by 39
Katsiki, N., Perakakis, N., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2019.07.009 · Cited by 38
Kahl, S., Ofstad, A. P., Zinman, B., Wanner, C., Schüler, E., Sattar, N., Inzucchi, S. E., & Roden, M. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14670 · Cited by 36
Arvanitakis, K., Koufakis, T., Kotsa, K., & Germanidis, G. S. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106261 · Cited by 39
Li, T., Fang, T., Xu, L., Liu, X., Li, X., Xue, M., Yu, X., Sun, B., & Chen, L. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.622153 · Cited by 37
Pathophysiological Mechanisms in Non-Alcoholic Fatty Liver Disease: From Drivers to Targets
Santos‐Laso, Á., Gutiérrez‐Larrañaga, M., Alonso‐Peña, M., Medina, J. M., Iruzubieta, P., Arias, M., López‐Hoyos, M., & Crespo, J. (2021) · Biomedicines · doi:10.3390/biomedicines10010046 · Cited by 40
Metabolic reprogramming of immune cells in MASH
Ma, C., Wang, S., Dong, B., & Tian, Y. (2025) · Hepatology · doi:10.1097/hep.0000000000001371 · Cited by 36
Antifibrotic effects of sodium-glucose cotransporter-2 inhibitors: A comprehensive review
Shakour, N., Karami, S., Iranshahi, M., Butler, A. E., & Sahebkar, A. (2023) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2023.102934 · Cited by 35
Sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver disease
Makri, E. S., Goulas, A., & Pοlyzos, S. A. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174272 · Cited by 32
Arai, T., Atsukawa, M., Tsubota, A., Mikami, S., Ono, H., Kawano, T., Yoshida, Y., Tanabe, T., Okubo, T., Hayama, K., et al. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188211000243 · Cited by 33
Konings, L. A. M., Matute, L. M., Boeren, A. M. P., van de Luitgaarden, I. A. T., Dirksmeier-Harinck, F., de Knegt, R. J., Tushuizen, M. E., Grobbee, D. E., Holleboom, A. G., & Cabezas, M. C. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70003 · Cited by 34
Zhang, E., Zhao, Y., & Hu, H. (2021) · Hepatology Communications · doi:10.1002/hep4.1611 · Cited by 32
Obesity Management in the Primary Prevention of Hepatocellular Carcinoma
Zunica, E. R. M., Heintz, E. C., Axelrod, C. L., & Kirwan, J. P. (2022) · Cancers · doi:10.3390/cancers14164051 · Cited by 32
Huynh, D. J., Renelus, B. D., & Jamorabo, D. S. (2023) · BMC Gastroenterology · doi:10.1186/s12876-023-03085-8 · Cited by 31
Misra, A., Kumar, A., Kuchay, M. S., Ghosh, A., Gulati, S., Choudhary, N. S., Dutta, D., Sharma, P., Vikram, N. K., Rastogi, A., et al. (2025) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2025.103209 · Cited by 28
The impact of sodium glucose co‐transporter 2 inhibitors on non‐alcoholic fatty liver disease
Chrysavgis, L., Papatheodoridi, A., Chatzigeorgiou, A., & Cholongitas, Ε. (2020) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15202 · Cited by 29
Exploring the links between types 2 diabetes and liver‐related complications: A comprehensive review
Sanchez, L. O., Chen, Y., Lassailly, G., & Qi, X. (2023) · United European Gastroenterology Journal · doi:10.1002/ueg2.12508 · Cited by 28
Review of current and new drugs for the treatment of metabolic-associated fatty liver disease
Gish, R. G., Fan, J., Dossaji, Z., Fichez, J., Laeeq, T., Chun, M. J., & Boursier, J. (2024) · Hepatology International · doi:10.1007/s12072-024-10698-y · Cited by 26
Papaetis, G. S. (2021) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad.2021.105314 · Cited by 25
Song, T., Chen, S., Zhao, H., Wang, F., Song, H., Tian, D., Yang, Q., & Qi, L. (2021) · Hepatology Research · doi:10.1111/hepr.13645 · Cited by 23
What Are the Current Pharmacological Therapies for Nonalcoholic Fatty Liver Disease?
David, D., & Eapen, C. E. (2020) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2020.09.001 · Cited by 26
Manka, P. P., Kaya, E., Canbay, A. E., & Syn, W. (2021) · Digestive Diseases and Sciences · doi:10.1007/s10620-021-07206-9 · Cited by 24
SGLT-2 Inhibitors for Non-Alcoholic Fatty Liver Disease: A Review
Xu, R., Lian, D., Xie, Y., Chen, Z., Wang, Y., Mu, L., Wang, Y., & Zhang, B. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2807134 · Cited by 25
Pokharel, A., Sudhamshu, K. C., Thapa, P., Karki, N., Shrestha, R., Jaishi, B., & Paudel, M. S. (2021) · Cureus · doi:10.7759/cureus.16687 · Cited by 29
Expanding the Use of SGLT2 Inhibitors in T2D Patients Across Clinical Settings
Cuttone, A., Cannavò, V., Abdullah, R. M. S., Fugazzotto, P., Arena, G., Brancati, S., Muscarà, A., Morace, C., Quartarone, C., Ruggeri, D., et al. (2025) · Cells · doi:10.3390/cells14090668 · Cited by 26
Amorim, R., Soares, P., Chavarria, D., Benfeito, S., Cagide, F., Teixeira, J., Oliveira, P. J., & Borges, F. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116723 · Cited by 26
Glucose Lowering Efficacy and Pleiotropic Effects of Sodium-Glucose Cotransporter 2 Inhibitors
Kuchay, M. S., Farooqui, K. J., Mishra, S. K., & Mithal, A. (2020) · Advances in experimental medicine and biology · doi:10.1007/5584_2020_479 · Cited by 22
Therapeutic Targets and Approaches to Manage Inflammation of NAFLD
Geng, W., Liao, W., Cao, X., & Yang, Y. (2025) · Biomedicines · doi:10.3390/biomedicines13020393 · Cited by 20
Altered lipid metabolism and the development of metabolic-associated fatty liver disease
Foster, C., Gagnon, C. A., & Ashraf, A. P. (2024) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000933 · Cited by 19
Gupta, U., Ruli, T. M., Buttar, D., Shoreibah, M., & Gray, M. E. (2023) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2023.11.007 · Cited by 21
Nanoparticle-based therapeutic strategies for chronic liver diseases: Advances and insights
Padmanaban, S., Baek, J.-W., Sahithya, C. S., Saipriya, C., Samrot, A. V., Gosu, V., Park, I., Radhakrishnan, K., & Kim, D. (2025) · Liver Research · doi:10.1016/j.livres.2025.04.002 · Cited by 22
Lee, C., Wu, M., Lui, D. T. W., Chan, D. S.-H., Fong, C. H.-Y., Shiu, S. W. M., Wong, Y., Lee, A. C., Lam, J. K. Y., Woo, Y. C., et al. (2022) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2021.0319 · Cited by 19
Lin, Y., Zhang, Z., Zhong, J.-Q., Wang, Z., Peng, Y.-T., Lin, Y.-M., Zhang, H.-P., & Tian, J.-Q. (2024) · PLoS ONE · doi:10.1371/journal.pone.0302155 · Cited by 19
A New Endemic of Concomitant Nonalcoholic Fatty Liver Disease and Chronic Hepatitis B
Hanif, H., Khan, M. M., Ali, M. J., Shah, P. A., Satiya, J., Lau, D., & Aslam, A. (2020) · Microorganisms · doi:10.3390/microorganisms8101526 · Cited by 21
Kuchay, M. S., Choudhary, N. S., Mishra, S. K., & Misra, A. (2020) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2020.11.015 · Cited by 18
Shinozaki, S., Tahara, T., Lefor, A. K., & Ogura, M. (2020) · The Journal of Medical Investigation · doi:10.2152/jmi.67.280 · Cited by 16
Therapeutic developments in metabolic dysfunction-associated fatty liver disease
Shi, Y., & Fan, J. (2022) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002091 · Cited by 17
Targeting Metabolism: Innovative Therapies for MASLD Unveiled
Wang, W., Gao, X., Niu, W., Yin, J., & He, K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094077 · Cited by 15
Kotsis, V., Jordan, J., Stabouli, S., Antza, C., Micić, D., Jelaković, B., Schlaich, M. P., Nilsson, P. M., Kreutz, R. H., Mancia, G., et al. (2019) · Journal of Hypertension · doi:10.1097/hjh.0000000000002279 · Cited by 15
Hooshmand Gharabagh, L., Shargh, A., Mohammad Hosseini Azar, M. R., & Esmaeili, A. (2024) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2023.102279 · Cited by 13
Metabolic-associated steatotic liver disease and hepatocellular carcinoma
Catalano, G., Chatzipanagiotou, O. P., Kawashima, J., & Pawlik, T. M. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2426680 · Cited by 14
Anastasiou, G., Stefanakis, K., Hill, M. A., & Mantzoros, C. S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156044 · Cited by 12
Harry, S., Lai, L. L., Mustapha, N. R. N., Aziz, Y. F. A., Vijayananthan, A., Rahmat, K., Mahadeva, S., & Chan, W. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.08.023 · Cited by 13
Self-citationEffects of anti-diabetic treatments in type 2 diabetes and fatty liver disease
Lamos, E. M., Kristan, M. M., Siamashvili, M., & Davis, S. N. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1917374 · Cited by 12
Kuchay, M. S., & Misra, A. (2022) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102446 · Cited by 13
Shikamura, M., Takayama, A., Takeuchi, M., & Kawakami, K. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15632 · Cited by 12
Papaetis, G. S., Picolos, M. K., & Sacharidou, A. (2025) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad/202298 · Cited by 14
Narrative review of current and emerging pharmacological therapies for nonalcoholic steatohepatitis
Satiya, J., Snyder, H. S., Singh, S. P., & Satapathy, S. K. (2021) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh-20-247 · Cited by 12
Metadata
- Authors
- Lai, L.-L., Vethakkan, S. R., Nik Mustapha, N. R., Mahadeva, S., & Chan, W.-K.
- Affiliations
- University of Malaya (MY)
- Corresponding author
- Vethakkan, Shireene Ratna
- Chan, Wah-Kheong
- Venue
- Digestive Diseases and Sciences
- Published
- 2019-01-25
- Volume
- 65
- Issue
- 2
- Pages
- 623-631
- ISSN
- 0163-2116 (ISSN-L)
- 1573-2568
- OpenAlex
- W2912523003
- Semantic Scholar
- 70a664f1746784da48173bec3333d56d3992f366
- Cited by
- 191
- References
- 33
- Citations by year
- 2026: 10 · 2025: 30 · 2024: 25 · 2023: 26 · 2022: 34 · 2021: 24 · 2020: 30 · 2019: 12
- FWCI
- 19.21
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Digestive Diseases and Sciences (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Malaya Special Research Fund (Project No.: BK006-2016, BKS067-2017)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- empagliflozin, nonalcoholic steatohepatitis, type 2 diabetes, SGLT2 inhibitors, liver histopathology, steatosis, liver fibrosis, ballooning, liver fat fraction, gamma-glutamyl transferase, renal glycosuria, pilot study
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Benzhydryl Compounds, Biopsy, Blood Glucose, Blood Pressure, Cholesterol, Diabetes Mellitus, Type 2, Female, gamma-Glutamyltransferase, Glucosides, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Liver, Male, Middle Aged, Pilot Projects, Body Mass Index, Treatment Outcome, Waist Circumference, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.